Space-id. Koln, Germany — A surprising breakthrough in HIV research was announced by a team of scientists from the University of Cologne and the German Center for InFection Research (DZIF). They managed to identify the newly coded antibodies. 04 _ A06 Which in the lab tests shows the ability to neutralize until 98,5% than over 300 variant HIV tested.
Discovery Content
- Antibodies 04 _ A06 found through studies on individuals known as Elite neutralizers — Those that naturally produce an antibody response to HlV are very broad and effective.
- The researchers filtered over 800 antibodies produced from over 5,000 B cells (B lymphocytes), then found that 04 _ A06 appeared as the most prominent of both the side coverage of the HlV variant and its ability to withstand the mechanism of virus resistance.
- Besides vitro testing, this antibody is also tested on humanized mix A mouse whose immune system was turned into a human being. As a result: the weight of the HlV virus in the rat's body became undetectable after the treatment of antibodies 04 _ A06.
- This antibody structure has a very long side of amino acids, allowing it to attach itself to the part of a virus that is often difficult to reach by other antibodies. Reached areas are so conservative by viruses that viruses don't easily mutate to avoid loss of importance.
Potential and Step Forward
- According to the computer model used by the research team, one antibody injection 04 _ A06 is predicted to provide more protection than 93% In clinical applications for HlV infections.
- These antibodies have been exclusively licensed to biotechnology companies. Vir Biotechnology, Inc. for further development.
- The researchers emphasize the importance of safety tests and effectiveness through clinical trials of humans, before it can be considered widely used — either as a therapy for people who have been infected with HlV or as preventive to those who are at high risk.
Impact and Challenge
This discovery is thought to be one of the most significant steps in the last decade of HlV research, because antibodies with this much rich coverage. If antibodies such as 04 _ A06 can be brought to clinical applications successfully, then it can open up new pathways in HlV treatment and perhaps also in prevention, including through passive immunization.
However, there are some challenges to be faced:
- Long-term security — The side effects of the use of antibodies in the long term need to be thoroughly examined.
- Production and distribution — Produced large amounts of antibodies with high standards and sent them to needy areas, especially in countries with limited resources.
- Cost — New technologies are usually expensive, and access to vulnerable populations must be taken care of to avoid inequality.
- Mutation virus — Although these antibodies show a lot of resistance to many variants, HlV is known for its ability to mutate; there's always a new variant risk emerging that can escape these antibodies.
Conclusion
Antibody discovery 04 _ A06 With the ability to neutralize almost all HlV variants in lab research and positive results on animal models, these antibodies bring new hope for therapy and HlV prevention.
Editor: Chatgpt
